Tests CAR T cells targeting two proteins in children with relapsed leukemia
Tests CD19x22 CAR T cell therapy in children with returning or treatment-resistant B-cell leukemia.
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Registry title
- CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 53 people, planned
- Started
- 27 Sept 2024
- Expected to end
- Dec 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- CD19x22 CAR T
- Record updated
- 28 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that came back or did not respond to treatment. They would receive a new CAR T-cell therapy.
- Age
- 3 months to 30 years
- Sex
- Males and non-pregnant, non-lactating females can join.
- Disease stage
- B precursor ALL that relapsed two or more times, relapsed after a bone marrow transplant, relapsed or did not respond after CAR T-cell therapy aimed at one target, or did not respond to standard therapy. CD19 and/or CD22 must be present on the last disease check.
- Earlier treatment
- At least 90 days must have passed since a previous CAR T infusion before cells are collected. Patient and/or parents may be declining a bone marrow transplant and prefer CAR T therapy.
- Biomarker or test result
- CD19 and/or CD22 present on the last relapsed or refractory disease evaluation.
Main reasons for not taking part
- Active, uncontrolled leukemia in the brain or spinal cord that keeps getting worse or causes symptoms
- Stem cell transplant less than 100 days ago, active graft-versus-host disease needing systemic treatment, or donor lymphocyte infusion less than 6 weeks ago
- Active, uncontrolled, life-threatening infection
- Severe organ problems, such as oxygen saturation below 90%, weak heart function, or poor liver or kidney function
- Known HIV infection or active hepatitis B or C infection
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Subjects must have a history of B precursor ALL with any of the following conditions:; Relapsed two or more times; Relapsed at any time after allogeneic bone marrow transplant (BMT); Relapse or refractory after single antigen targeting CAR T cell therapy; 90 days must have elapsed post previous CAR infusion prior to apheresis. d. Refractory to standard therapy as determined by the treating physician. e. Patient and/or parents declining BMT options and would prefer CAR T Therapy
- CD19 and/or CD22 present on last relapsed/refractory disease evaluation
- Performance score (Lansky or Karnofsky ≥ 50%; or Eastern Cooperative Oncology Group (ECOG) must be ≤2)
- Meets criteria for potential leukapheresis collection or has leukapheresis product previously collected and stored per recommended guidelines
- Males OR non-pregnant, non-lactating females
- Aged 3 months to 30 years (inclusive) at time of consent and enrollment
- Provision of a signed and dated consent form from parent or guardian (patients < 18), the patient themselves (> 18), or legally authorized representative (patient > 18 who lack decision-making capacity) after standard of care (SOC) screening assessments are performed
- Stated willingness to comply with all study procedures and be available for the duration of the study
- Willingness to participate in long-term follow-up protocol
Who cannot take part
- Active, uncontrolled central nervous system (CNS) leukemia that is progressive despite other therapies or leading to CNS symptoms (including but not limited to: seizures, paresis, aphasia, hemorrhage, dementia, psychosis, or movement disorders) as determined by the treating physician at eligibility, prior to lymphodepleting chemotherapy (LD chemo), and pre- CD19x22 CAR T cell infusion
- Subjects of childbearing or child-fathering potential that are not willing to practice birth control from the time of enrollment on this study and for 12 months after receiving the investigational product
- Active, uncontrolled, life-threatening infection that at the determination of the treating physician would preclude safe apheresis or tolerance of lymphodepleting chemotherapy, cell infusion, or increased risk of cytokine release syndrome
- Known HIV infection or active Hepatitis B or Hepatitis C infection
- History of allogeneic stem cell transplantation prior to apheresis that meet the following criteria:; Less than 100 days post-transplant; Evidence of active Graft-versus-Host Disease (GvHD) requiring systemic therapy; Less than 6 weeks post donor lymphocyte infusion (DLI)
- Evidence of severe organ dysfunction defined by:; Baseline oxygen saturation of < 90% on room air; Myocardial dysfunction (based on age standards): Ejection fraction ≤ 40% or shortening fraction ≤ 28%, evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and clinically significant electrocardiogram (ECG or EKG) findings; Transaminases > 10x upper limit of normal (ULN) or bilirubin > 5x the ULN, unless thought to be related to primary disease; Estimated Creatinine (Cr) clearance < 60 mL/min/1.73 m2 (if nuclear medicine GFR or other more specific testing exceeds this level than it can supersede the estimated clearance)
Where in United States
- Children's Hospital ColoradoAurora, United StatesContact: Vanessa Fabrizio, MDTaking people
About the trial
What the trial wants to find out
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
The 2 groups in the trial
- High Disease Burden CohortTreatment being tested
≥25% bone marrow lymphoblasts and/or non-CNS extramedullary disease. Dose escalation will proceed independently within each cohort using the Bayesian Optimal Interval (BOIN)design. Dose begins at DL -1(1x10\^5 cells/kg).
Treatment: CD19x22 CAR T
- Low Disease Burden CohortTreatment being tested
\<25% bone marrow lymphoblasts and no non-CNS extramedullary disease. Dose escalation will proceed independently within each cohort using the Bayesian Optimal Interval (BOIN)design. Dose begins at DL1 (3x10\^5 cells/kg).
Treatment: CD19x22 CAR T
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Phase I Dose Escalation and Preliminary Efficacy Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Pediatric Patients With Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Plain-language title
- Tests CAR T cells targeting two proteins in children with relapsed leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 November 2025